Peptide Injections

What are peptide injections?

Peptide injections deliver short chains of amino acids through a needle, typically into subcutaneous tissue as specified by the compound's protocol [7][8]. The term "peptide" refers to a molecular class, amino acid chains shorter than proteins, and does not imply safety, efficacy or regulatory approval [7][8][23].

You will learn the difference between registered therapeutic peptides and unregistered products, how injection works, and what practical steps to take before purchasing.

Injection avoids digestive breakdown that fragments some compounds, explaining why insulin has been administered this way for decades. Therapeutic peptide medicines with SAHPRA registration, defined indications and manufacturing standards exist alongside unregistered products marketed online for recovery, anti-ageing or performance that lack robust human evidence [1][2][15].

This distinction affects purchasing decisions. Authorised products include labelled storage conditions, reconstitution instructions where applicable, and documented purity and sterility standards. Unregistered vials or powders sold for research create additional risks involving concentration errors, diluent choice, contamination and uncertain stability [7][8][23]. For practical guidance on preparing lyophilised powders safely, see our guide on how to reconstitute peptides with bacteriostatic water.

Why are peptides injected?

Many peptide molecules break down in the digestive tract, making oral absorption insufficient for systemic exposure [4][7][8]. Injection bypasses first-pass metabolism, allowing the compound to reach circulation intact, which is why insulin has been delivered subcutaneously for decades [7][8].

This rationale is pharmacological, not universal. Some peptide medicines are being developed in oral formulations, so the appropriate route is compound-specific and must follow registered product information [4][7][8]. A 2026 gerontology review indicates non-approved peptides have promising mechanisms and preclinical findings but limited clinical evidence, inadequate long-term safety data and a lack of systematic validation; it specifically identifies BPC-157 and TB-500 as lacking adequate human clinical trials [21]. For weight-management peptides, human evidence is strongest: semaglutide and tirzepatide trials from 2024–2026 measure body-weight change, waist circumference, glycaemic endpoints and cardiometabolic risk factors [4][5][6].

Route choice does not establish benefit. Subcutaneous administration is specified for licensed semaglutide and tirzepatide products [7][8], while other compounds may lack any authorised route or human dosing data. For tirzepatide-specific escalation guidance, see our tirzepatide trial escalation guide. To understand what batch documentation can and cannot verify, read how to verify a peptide Certificate of Analysis.

Subcutaneous or intramuscular: which route applies?

Most injectable peptides discussed in consumer settings are administered subcutaneously, yet the correct route is always compound-specific and must follow the registered product label or clinical protocol [7][8][23]. Subcutaneous delivery deposits medication into the fatty layer beneath the skin, while intramuscular delivery places it directly into muscle tissue [7][8].

Route	Tissue layer	Common sites	Typical equipment	Practical implications
Subcutaneous	Fatty tissue beneath the skin	Abdomen, thigh, upper arm [24][25]	Prefilled pen or fine pen needle (e.g., 6 mm × 31G) [15]	Slower, steadier absorption; suitable for self-administration; sites must be rotated [24][25]
Intramuscular	Muscle tissue	Varies by clinical protocol	Longer needle selected by a healthcare professional	Faster absorption; requires trained technique; never substituted for subcutaneous unless the label specifically directs it

Current Wegovy and Zepbound labels specify subcutaneous administration and explicitly warn against intramuscular or intravenous injection [24][25]. Although many consumer peptide protocols describe subcutaneous administration, some compounds may specify intramuscular or another route within an approved clinical protocol [23]. Do not change the route of any product unless the registered documentation or a qualified healthcare professional explicitly instructs it. A fine needle does not by itself make intramuscular injection appropriate.

Which needles and syringes are used?

Needle and syringe selection depends on whether the product is a prefilled pen or a vial requiring reconstitution. Authorised pen devices use manufacturer-specified pen needles, while vial-based administration requires a sterile syringe and needle selected by a healthcare professional according to the formulation and injection route [15][24][25]. We list Body Pharm 6 mm × 31G pen needles in boxes of 30; see the product page for the current price, though our product page does not establish compatibility with every pen or authorisation status [15]. A 6 mm × 31G pen needle is not automatically compatible with every injection device or peptide formulation [24][25]. Never reuse needles or share pens; dispose of used sharps in an approved container according to local municipal or healthcare guidance. Always confirm needle compatibility, sterility and measurement units with a pharmacist or clinician before injecting, and consult our semaglutide trial and label titration guide or tirzepatide trial escalation guide to match the syringe scale to the scheduled dose.

Reconstitution, storage and cold-chain handling

Lyophilised peptide powders require reconstitution with a specific diluent, aseptic technique and product-defined storage conditions before and after mixing; the process is compound-specific and should not be attempted using generic internet instructions [7][8][9].

Reconstitution basics

Freeze-dried or lyophilised peptides arrive as powder in vials that must be mixed with sterile water or bacteriostatic water before injection. The correct diluent volume, mixing method and beyond-use date depend on the specific product's formulation and stability data. We do not stock reconstituted vials; our HD Labs products arrive as lyophilised powder requiring preparation. Always follow the manufacturer's instructions for diluent type, reconstitution technique and concentration verification; never assume that a 2 mg vial plus 1 ml water equals a standard dose.

Storage before and after reconstitution

Storage requirements differ between unopened lyophilised powder and reconstituted solution. The 2025 Wegovy label specifies refrigeration at 2–8°C, protection from light, no freezing, and up to 28 days at 8–30°C before cap removal [7]. The 2025 Zepbound label specifies refrigeration at 2–8°C, protection from light, no freezing, and up to 21 days at no more than 30°C for single-dose presentations [8]. The 2025 Egrifta WR label specifies room-temperature storage at 20–25°C for unconstituted powder, with reconstituted solution discarded after 7 days [9]. These instructions apply only to their named products and must not be transferred to unrelated peptides.

Cold-chain handling from BeSkinny

We handle products cold-chain from storage through dispatch. Weight-loss pens ship with a gel pack for cold-chain integrity. Orders placed and paid before 12:00 on a business day typically ship same-day; major metros generally receive delivery next working day, outlying areas 2–5 working days [16][18][19]. Inspect your parcel promptly upon arrival. Refrigerate only when the product label requires it, avoid freezing, and contact us and a pharmacist if the package arrives warm, damaged or without batch documentation. Our shipping process supports temperature maintenance in transit; it does not replace following the product's own labelled storage instructions after delivery.

A Certificate of Analysis documents batch identity and purity, not sterility or stability; learn how to verify a peptide Certificate of Analysis before relying on any seller's documentation.

South Africa peptide comparison matrix

Injectable peptides differ sharply in regulatory standing, evidence quality and practical handling. The table below compares thirteen commonly discussed compounds by the criteria that determine whether a product matches its marketed purpose and your risk tolerance.

Compound	Intended use or marketed purpose	Current SA regulatory status	Human evidence quality	Stated route	Stated storage	CoA available	Current price
Semaglutide	Type 2 diabetes; weight management (off-label)	Registered for diabetes (Ozempic); Wegovy for weight management not confirmed in SAHPRA 2024-2026 notices [1][2]	Strong: 2024-2026 trials measure body-weight change, glycaemic endpoints, cardiometabolic risk [4]	Subcutaneous [7]	2–8°C; up to 28 days at 8–30°C before cap removal [7]	Yes, request on product page	See live product page
Tirzepatide	Type 2 diabetes; weight management (off-label)	Registered for diabetes (Mounjaro) per November 2024; not confirmed imported or registered for weight management [1][2]	Strong: 2024-2026 trials measure weight change, waist circumference, safety [4]	Subcutaneous [8]	2–8°C; up to 21 days at ≤30°C for single-dose pens [8]	Yes, request on product page	See live product page
Retatrutide	Weight management	Not identified in SAHPRA 2024-2026 notices as registered [2]	Moderate: Phase 2/3 obesity programmes measure percentage weight change; marketing claims exceed trial scope [4]	Subcutaneous (trial protocol)	Verify current product documentation	Yes, request on product page	See live product page
CagriSema	Weight management	Not identified in SAHPRA 2024-2026 notices as registered [2]	Moderate: REDEFINE-1 (68 weeks, 3,417 adults) and REDEFINE-4 (84 weeks vs tirzepatide) measure efficacy and safety; compound-specific marketing requires careful separation from trial evidence [5]	Subcutaneous (trial protocol)	Verify current product documentation	Yes, request on product page	See live product page
BPC-157	Recovery, healing, performance	Listed in SAHPRA May 2026 notice as illegally marketed unregistered peptide [2]	Weak: 2025 systematic review found 35 of 36 studies preclinical; one clinical report only [20]	Verify current product documentation	Verify current product documentation	Yes, request on product page	See live product page
TB-500	Recovery, healing, performance	Listed in SAHPRA May 2026 notice as illegally marketed unregistered peptide [2]	Weak: 2026 gerontology review identifies inadequate human clinical trials [21]	Verify current product documentation	Verify current product documentation	Yes, request on product page	See live product page
AOD-9604	Fat metabolism	Listed in SAHPRA May 2026 notice as illegally marketed unregistered peptide [2]	Limited human data; mechanism inferred from animal studies	Verify current product documentation	Verify current product documentation	Yes, request on product page	See live product page
GHK-Cu	Skin repair, anti-ageing	Listed in SAHPRA May 2026 notice as illegally marketed unregistered peptide [2]	2026 meta-analysis of oral/topical peptides (19 trials, 1,341 participants) shows modest skin outcomes; does not establish injectable efficacy or safety [22]	Verify current product documentation	Verify current product documentation	Yes, request on product page	See live product page
CJC-1295/Ipamorelin	Growth hormone release, body composition	Listed in SAHPRA May 2026 notice as illegally marketed unregistered peptide [2]	Limited controlled human trials; mechanism supported by preclinical data	Verify current product documentation	Verify current product documentation	Yes, request on product page	See live product page
MOTS-C	Metabolic health, longevity	Not identified in SAHPRA 2024-2026 notices as registered	Preclinical and mechanistic only; no adequate human clinical trials	Verify current product documentation	Verify current product documentation	Yes, request on product page	See live product page
NAD+	Cellular energy, longevity	Not identified in SAHPRA 2024-2026 notices as registered	Limited human evidence for injectable form; oral and IV routes more commonly studied	Verify current product documentation	Verify current product documentation	Yes, request on product page	See live product page
Tesamorelin	HIV-associated lipodystrophy (visceral adipose tissue)	Verify current SAHPRA product database; Egrifta WR registered in US with specific indication [6][9]	Moderate for indicated use: trials measure visceral adipose tissue reduction in HIV-associated lipodystrophy; not general weight loss or wellness [6]	Subcutaneous [9]	20–25°C unconstituted; discard reconstituted solution after 7 days [9]	Verify current product documentation	See live product page
Somatropin/HGH	Growth hormone deficiency, specific indications	Verify current SAHPRA product database; prescription medicine with scheduling requirements	Strong for approved indications: trials measure growth, lean mass, disease-specific outcomes; not general wellness or performance	Verify current product documentation	Verify current product documentation	Verify current product documentation	See live product page

How to read this matrix

Regulatory status determines lawful sale and prescriber involvement. SAHPRA's 8 November 2024 notice states that compounding a medicine with an active ingredient not contained in a registered product is illegal, and sale of a registerable unregistered medicine is an offence under section 29 of the Medicines and Related Substances Act [1]. The 5 March 2025 intention to declare compounded GLP-1 or GLP-1/GIP agonists undesirable cites sterile-manufacturing, identity, potency and safety concerns [13].

Human evidence is graded by whether 2024-2026 controlled trials measured the claimed outcome in the population and route proposed. Mechanistic plausibility, animal data and in-vitro findings do not translate to human efficacy [20][21].

CoA availability documents batch identity and purity by third-party testing; it does not establish sterility, endotoxin control, regulatory approval or clinical effectiveness [10][11][12].

Prices change; verify current figures on the live product page before purchase [15][16].

Browse wellness and recovery peptides to compare compounds by application, or view the full peptide and weight-loss injection range for live stock, strengths and documentation.

How to assess evidence and regulatory status

A four-step framework separates marketing claims from verified facts: identify the exact compound and formulation; check whether 2024–2026 human clinical evidence supports the claimed outcome; verify current South African regulatory and prescription status through SAHPRA; then confirm whether batch-level documentation is available. This process distinguishes approved medical treatments from research-grade or unregistered products.

Step 1: Identify the compound and formulation

"Peptide" describes a molecular class, not a specific medicine. Semaglutide, tirzepatide, BPC-157 and TB-500 are distinct molecules with different biological targets, manufacturing requirements and evidence bases. Check that the product name, sequence or INN matches the claim. A 2025 systematic review of BPC-157 found 35 of 36 included studies were preclinical; only one was a clinical report, so broad human recovery claims are unsupported [20].

Step 2: Verify human clinical evidence

Human evidence requires controlled trials measuring the claimed endpoint in the proposed population and route. Mechanistic plausibility, animal data and in-vitro findings do not establish human efficacy [21]. For weight-loss peptides, 2024–2026 trials measure percentage body-weight change, categorical thresholds and cardiometabolic risk [4][5]. A 2026 meta-analysis of oral and topical peptides reported modest skin outcomes across 19 randomised trials, but these findings do not transfer to injectable products [22].

Step 3: Check South African regulatory status

SAHPRA's 8 November 2024 notice states that Ozempic (semaglutide) and Mounjaro (tirzepatide) are registered for type 2 diabetes, not weight management, and that compounding with unregistered active ingredients is illegal [1]. The 26 May 2026 public information page lists BPC-157, TB-500, CJC-1295, Ipamorelin, PT-141, AOD-9604, Selank and Semax as illegally marketed unregistered examples [2]. A product's presence on an online store does not indicate SAHPRA registration.

Step 4: Assess seller documentation

A Certificate of Analysis documents batch identity and purity by mass spectrometry and HPLC, but it does not prove sterility, endotoxin control, aseptic manufacture or clinical effectiveness [10][11][12]. We state that every batch is third-party tested for purity and identity, with a CoA available on the relevant product page or on request [15]. This supports a documentation check; it does not replace regulatory verification or medical advice.

Research-grade peptides are distinct from approved medicines. BPC-157 product information provides compound-specific details for one commonly searched recovery peptide. For readers assessing retatrutide specifically, retatrutide side effects reported in the Phase 2 trial offers a dedicated evidence-focused follow-up.

What to check before buying peptide injections

Confirm the exact compound, strength and intended use, then verify the current SAHPRA registration status, batch documentation and cold-chain capability before paying for any peptide injection in South Africa. We are an online reseller stocking Body Pharm and HD Labs at fixed ZAR pricing, not an open marketplace.

Buyer verification checklist

• Compound and strength: Match the vial or pen label to the specific molecule and milligram strength you researched; similar names or strengths are not interchangeable.

Peptide injections: practical FAQs

Peptide injections are most commonly administered subcutaneously, though the exact route, frequency and storage requirements depend entirely on the specific compound and whether it is a registered medicine or an unregistered product [7][8][23].

Are peptide injections always subcutaneous?

No. While licensed semaglutide and tirzepatide pens are administered subcutaneously into the abdomen, thigh or upper arm [7][8], other compounds may have different authorised routes in specific clinical protocols. Unregistered peptides marketed online often lack defined administration guidance, and claims about intramuscular or other routes should be treated as unverified [23].

Can all peptides be injected?

Not all peptides are formulated for injection. Some peptide medicines are developed in oral or other formulations, and the injectable route is chosen for specific pharmacological reasons to avoid degradation by digestive enzymes and to achieve predictable systemic exposure [4][7][8]. The suitability of injection depends on the compound, its formulation and its registration status.

Do peptide injections need refrigeration?

Storage requirements are compound-specific. Licensed semaglutide pens require refrigeration at 2–8°C and may be kept at 8–30°C for up to 28 days before first use [7]. Licensed tirzepatide pens require similar cold storage but permit only 21 days at no more than 30°C for single-dose presentations [8]. Tesamorelin, by contrast, is stored at room temperature (20–25°C) [9]. Unregistered peptides lack standardised storage specifications, so product labels and seller guidance must be followed precisely.

How often are peptide injections used?

Dosing frequency varies by compound and indication. Licensed weight-management and diabetes medicines typically follow weekly schedules [7][8]. Other peptides may require daily or multiple-weekly administration depending on the specific protocol. There is no universal frequency that applies across all peptide injections.

Can I buy peptide injections in South Africa?

Peptide injections can be purchased online from South Africa-based sellers, but legal status varies. SAHPRA has registered semaglutide and tirzepatide for type 2 diabetes, though not all strengths or indications are available through official channels [1]. Many peptides, including BPC-157, TB-500, CJC-1295 and others, are explicitly listed by SAHPRA as illegally marketed unregistered products [2]. We stock Body Pharm and HD Labs products, ship nationwide via The Courier Guy and Aramex, and accept orders online with EFT, card or Bitcoin payment [16][18][19].

Is a CoA enough to prove a product is safe?

A Certificate of Analysis documents reported batch identity and purity, typically including mass spectrometry and HPLC results [10][11]. However, it does not by itself establish sterility, endotoxin control, aseptic manufacture or finished-product suitability for human injection [10][12]. Additional validated testing would be required to assess those safety parameters. We state that every batch is third-party tested for purity and identity, with a CoA available on the relevant product page or on request [18].

Browse the full peptide and weight-loss injection range to view current compounds, strengths and availability, or see BPC-157 product information for details on one commonly searched recovery peptide.

Key takeaways

• Peptide injections deliver amino acid chains subcutaneously or intramuscularly, depending on the specific compound's protocol.
• Registered therapeutic peptides like semaglutide and tirzepatide have strong human evidence and SAHPRA approval for specific indications, while unregistered products like BPC-157 and TB-500 are listed as illegally marketed and lack adequate clinical trials.
• Storage, reconstitution and administration are compound-specific; always follow the registered product label or clinical protocol.
• Verify the exact compound, regulatory status, human evidence and batch documentation before any purchase.

Choose the next step carefully

Peptide injections require compound-specific knowledge, verified documentation and professional medical guidance before any purchase decision.

We stock Body Pharm and HD Labs products, with every batch stated to be third-party tested for purity and identity. A Certificate of Analysis is available on the relevant product page or on request via email before you buy [18]. Products are handled cold-chain from storage through dispatch; weight-loss pens ship with a gel pack for temperature integrity [18]. We ship within South Africa only, using The Courier Guy and Aramex. Orders placed and paid before 12:00 on a business day typically dispatch same-day, with major metros generally receiving delivery next day and outlying areas within 2–5 working days [16][18][19].

Prices and availability change. Check the live product page for current ZAR pricing, stock status and any compound-specific storage or handling instructions. Discuss intended use, contraindications and monitoring with a qualified healthcare professional before ordering.

Shop the full range, every compound, in the strengths that matter

Sources

• [1] SAHPRA's position on GLP1 and GIP-GLP1 products that are compounded, substandard and falsified, SAHPRA, 8 November 2024
• [2] Peptide Products – Public Information, SAHPRA, 26 May 2026
• [4] Triple Agonism Based Therapies for Obesity, NIH/PMC, 28 July 2025
• [5] REDEFINE-1 and REDEFINE-4 trial records, ClinicalTrials.gov
• [6] EGRIFTA WR prescribing information, US FDA, 2025
• [7] WEGOVY semaglutide prescribing information, US FDA, 2025
• [8] ZEPBOUND tirzepatide prescribing information, US FDA, 2025
• [9] EGRIFTA WR tesamorelin prescribing information, US FDA, 2025
• [10] Peptide purity: what a COA can and cannot confirm, Halftime Health, 13 May 2026
• [11] How Peptide Vendors Test Purity and Quality Control, ChemVerify, 12 April 2026
• [12] Peptide Quality Control: What to Check Beyond Purity, MolChanges, 23 September 2026
• [13] Intention to Declare Medicines Compounded in terms of Section 14(4) Containing GLP-1 or GLP-1/GIP Agonists Undesirable, SAHPRA, 5 March 2025
• [15] BeSkinny: Peptides and Weight-Loss Injections South Africa, retrieved October 2026
• [16] Body Pharm Peptides South Africa, BeSkinny, 9 June 2026
• [18] About BeSkinny: Peptides and Weight-Loss Injections, South Africa, retrieved October 2026
• [19] Peptides for Sale South Africa, BeSkinny, retrieved October 2026
• [20] BPC-157 for Orthopaedic Applications: A Systematic Review, HSS Journal, 2025
• [21] Therapeutic peptides in gerontology: mechanisms and clinical perspectives, Frontiers in Aging, 7 April 2026
• [22] Peptide supplementation and skin outcomes meta-analysis, Frontiers in Medicine, 2026
• [23] SAHPRA Peptide Products – Public Information, 26 May 2026
• [24] ZEPBOUND prescribing information, US FDA, 2025
• [25] WEGOVY prescribing information, US FDA, 2025